The Role of Long Non-coding RNA in Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 1237
Special Issue Editor
Special Issue Information
Dear Colleagues,
The role of lncRNAs is still unclear and currently under investigation in cancer progression, dormancy, and metastasis. Metastatic relapse is the major cause of mortality in patients with cancer and occurs due to the metastatic reactivation of dormant tumor cells. Early dissemination of tumor cells undergoing a protected period of dormancy in the target organs potentially explains this prevalent clinical behavior. LncRNAs are a class of transcripts with diverse and largely uncharacterized biological functions involved in various biological processes and have been proposed to be key players in diseases including cancers. Through crosstalk with chromatin, DNA, RNA species and proteins, lncRNAs play an important role in chromatin remodeling, as well as transcriptional and post-transcriptional regulation. The lncRNAs mediated genetic or epigenetic alterations in disseminated tumor cells regulate metastatic niches which play a significant role to define the fate of dormant tumor cells in reactivation. The rate-limiting step of the metastatic process can be influenced by various immune cells in a tumor microenvironment (TME). Despite all these findings, the role of tumor intrinsic LncRNAs in the regulation of metastatic reactivation and immune evasion remains unclear. Understanding the mechanisms of lncRNAs during cancer dormancy, metastasis and tumor immune microenvironment would be highly valuable to identify novel targets to combat cancer metastasis and relapse.
Dr. Dhiraj Kumar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- LncRNAs
- cancer
- dormancy
- metastasis
- tumor immune microenvironment
- niche
